NCT04554511

Brief Summary

This study aims to evaluate prognostic factors for overall survival and explore risk progression-free survival in ENKTL, and establish a prognostic predictive nomogram for ENKTL patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 28, 2020

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

September 12, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 18, 2020

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2024

Completed
Last Updated

June 18, 2023

Status Verified

June 1, 2023

Enrollment Period

3.3 years

First QC Date

September 12, 2020

Last Update Submit

June 15, 2023

Conditions

Extranodal NK/T-cell Lymphoma

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    Time between the date of diagnosis and any kinds of death

    5 year

Secondary Outcomes (1)

  • Progression-free survival

    5 year

Study Arms (2)

Training cohort

Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.

Validation Cohort

Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

1. Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020; 2. Patients older than 18 years.

You may qualify if:

  • Patients newly diagnosed with ENKTL
  • Patients diagnosed between January 1, 2000 and August 31, 2020
  • Patients older than 18 years

You may not qualify if:

  • Patients who did not have complete clinical information or immunohistochemistry, or who were lost follow-up immediately after treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China

RECRUITING

MeSH Terms

Conditions

Lymphoma, Extranodal NK-T-Cell

Condition Hierarchy (Ancestors)

Lymphoma, T-CellLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasms

Study Officials

  • Hua Wang

    Sun Yat-sen University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Hua Wang

CONTACT

+862087342462wanghua@sysucc.org.cn

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
associate chief physician

Study Record Dates

First Submitted

September 12, 2020

First Posted

September 18, 2020

Study Start

August 28, 2020

Primary Completion

January 1, 2024

Study Completion

January 1, 2024

Last Updated

June 18, 2023

Record last verified: 2023-06

Locations

CN(1)